Role of Limited Sublobar Resection for Early-Stage Lung Cancer: Steady Progress

2014 ◽  
Vol 32 (23) ◽  
pp. 2403-2404 ◽  
Author(s):  
Hisao Asamura
Keyword(s):  
Lung Cancer ◽  
Early Stage ◽  
Sublobar Resection ◽  
Early Stage Lung Cancer ◽  
Stage Lung Cancer

scholarly journals Roles of NOTCH1 as a Therapeutic Target and a Biomarker for Lung Cancer: Controversies and Perspectives

2015 ◽  
Vol 2015 ◽  
pp. 1-8 ◽  
Author(s):  
Lixia Guo ◽  
Ting Zhang ◽  
Ying Xiong ◽  
Yanan Yang
Keyword(s):  
Lung Cancer ◽  
Therapeutic Target ◽  
Early Stage ◽  
Small Population ◽  
Cancer Development ◽  
Potential Usefulness ◽  
Early Stage Lung Cancer ◽  
Human Carcinogenesis ◽  
Stage Lung Cancer

Lung cancer is one of the most common types of human malignancies and the leading cause of cancer-related death. Patients with surgically resectable early stage lung cancer are more likely curable, but currently only a small population of patients can be diagnosed at such a stage, partly due to our incomplete understanding of the biology of lung cancer and the lack of diagnostic and prognostic biomarkers. Recent studies have shown that NOTCH1 is a critical regulator of human carcinogenesis and has been implicated in multiple steps of cancer development and progression. Herein, we review recent findings about the role of NOTCH1 in lung cancer and discuss its potential usefulness as both a therapeutic target and a biomarker for lung cancer.

scholarly journals A review of the role of MRI in diagnosis and treatment of early stage lung cancer

2020 ◽  
Vol 24 ◽  
pp. 16-22 ◽  
Author(s):  
Austin J. Sim ◽  
Evangelia Kaza ◽  
Lisa Singer ◽  
Stephen A. Rosenberg
Keyword(s):  
Lung Cancer ◽  
Early Stage ◽  
Diagnosis And Treatment ◽  
Early Stage Lung Cancer ◽  
Stage Lung Cancer

PD-1 Blockade in Early-Stage Lung Cancer

2019 ◽  
Vol 70 (1) ◽  
pp. 425-435 ◽  
Author(s):  
Samuel Rosner ◽  
Joshua E. Reuss ◽  
Patrick M. Forde
Keyword(s):  
Lung Cancer ◽  
Early Stage ◽  
Immune Checkpoint Blockade ◽  
Advanced Lung Cancer ◽  
Early Stage Lung Cancer ◽  
Early Results ◽  
Stage Disease ◽  
Relapse Rates ◽  
Stage Lung Cancer

Early-stage non–small cell lung cancer is a potentially curable disease, but with relapse rates exceeding 50% with standard treatments, this is a patient population in critical need of therapy innovation. Immunotherapy with immune checkpoint blockade has revolutionized the treatment strategy for advanced lung cancer. However, the role of this therapy in earlier-stage disease is largely unknown. The study of immunotherapy in earlier-stage disease has many advantages, including assessment of pathologic response and incorporation of translational scientific analyses to evaluate antitumor immune responses. Multiple clinical trials are currently under way, with promising early results.

Sublobar Resection for Early-Stage Lung Cancer

2010 ◽  
Vol 22 (1) ◽  
pp. 22-31 ◽  
Author(s):  
Matthew J. Schuchert ◽  
Ghulam Abbas ◽  
Arjun Pennathur ◽  
Katie S. Nason ◽  
David O. Wilson ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Early Stage ◽  
Sublobar Resection ◽  
Early Stage Lung Cancer ◽  
Stage Lung Cancer
Sign in / Sign up

Export Citation Format

Share Document